Search
In an Australian-first study, researchers at The Kids Research Institute Australia are investigating the effects of COVID-19 on the wellbeing of more than 2,000 families in the northern suburbs of Perth, measuring their perceived stress, financial hardship and family functioning during the pandemic.
At least 2,000 WA healthcare workers will help test whether an existing tuberculosis vaccine can reduce their chance of COVID-19 infection, lessen the severity of symptoms and boost immunity.
Like many of us, consumer and community advocate Catherine Hughes is worried about the impact of COVID-19. So she joined Australia’s first COVID-19 consumer reference group to be a voice for the community.
The speed with which research projects on the coronavirus have been put together has consumer advocates concerned that a vital voice will be missing – that of the community.
Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.
Comparatively few children have tested positive for coronavirus (COVID-19). Here’s what we know so far about how children are affected.
The Kids Research Institute Australia is pleased to share in $490,000 in State Government funding designed to provide vital support to WA’s innovation sector in the wake of COVID-19.
Australia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.
Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies.
The ability for vaccines to protect against infectious diseases varies among individuals, but computational models employed to inform policy typically do not account for this variation. Here we examine this issue: we implement a model of vaccine efficacy developed in the context of SARS-CoV-2 in order to evaluate the general implications of modelling correlates of protection on the individual level.